Comunicati stampa

febbraio 12, 2018

Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer

febbraio 1, 2018

Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer

gennaio 26, 2018

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

gennaio 22, 2018

Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer

dicembre 7, 2017

Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer

dicembre 5, 2017

Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis

novembre 17, 2017

Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017

settembre 6, 2017

Advanced Accelerator Applications Announces First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera®)

agosto 31, 2017

Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017

agosto 28, 2017

Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®)

luglio 27, 2017

Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA

luglio 21, 2017

Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

maggio 31, 2017

Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017

maggio 30, 2017

Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

maggio 29, 2017

Christine Mikail entra a far parte del Board of Director di Advanced Accelerator Applications

maggio 18, 2017

Advanced Accelerator Applications Receives 2017 Industry Innovation Award from National Organization for Rare Disorders for NETSPOT®, a Diagnostic Drug for Neuroendocrine Tumors

marzo 30, 2017

Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177

marzo 23, 2017

Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT® Launch Success

marzo 15, 2017

Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23

marzo 6, 2017

Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS

marzo 1, 2017

Advanced Accelerator Applications Announces Addition of NETSPOT® to National Comprehensive Cancer Network® Guidelines for Evaluation of NETs

gennaio 12, 2017

Advanced Accelerator Applications annuncia la pubblicazione dei risultati dello studio di Fase III NETTER-1 relativo al Lutathera® sul New England Journal of Medicine

gennaio 9, 2017

Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA

gennaio 4, 2017

Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference

dicembre 21, 2016

Advanced Accelerator Applications riceve la lettera di risposta completa dalla FDA per Lutathera®, un trattamento sperimentale per i tumori neuroendocrini